Letermovir: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
AIFA (Italy), DMC (Denmark) and G-BA (Germany), among others, recommended or restricted letermovir, while CONITEC (Brazil) and PBAC (Australia) did not recommend it.
Assessment has run over 8.8 years, from 13 Feb 2017 at AWMSG (Wales) to 17 Dec 2025 at HAS (France).
NYE METODER (Norway) changed its position: recommended on 24 Feb 2019, not recommended by 21 Jan 2024.
Every one of the eight highest-volume agencies in this archive has a record for letermovir.
Not every gap is a refusal: for letermovir, 1 submission was never made and 1 was withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
The file is active: 12 of 28 records date from 2023 or later.
7 distinct indication wordings are recorded for letermovir by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
2 of these 28 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess letermovir, on 13 Feb 2017; G-BA (Germany) did not open a file until 6 Jun 2024 — a wide spread of 7.3 years between the earliest and latest system to look at it.
The record arrives in waves: 5 separate years each carry two or more decisions, spread across 8 years in total.
8 of the 14 agencies here assessed letermovir more than once, G-BA (Germany) most often at 4 entries — repeat review is the norm for this molecule rather than the exception.
letermovir has been through 14 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for letermovir reads 12 recommended, 4 restricted, 4 not recommended and 3 no benefit, with 5 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| G-BA (Germany) | 6 Nov 2025 | Prevymis — benefit assessment §35a | added benefit: not proven | source |
| SMC (Scotland) | 11 Aug 2025 | For prophylaxis of cytomegalovirus (CMV) disease in CMV-seronegative adults who have received a kidney transplant from a CMV-seropositive donor [D+/R-]. | not recommended | source |
| NICE (England) | 23 Jul 2025 | NICE TA1082 | terminated appraisal | source |
| CIPM (Spain) | 23 Oct 2024 | Indicaciones terapéuticas autorizadas: PREVYMIS está indicado para la profilaxis de la reactivación del citomegalovirus … | not financed by the SNS · art. 92 d, e | source |
| AIFA (Italy) | 17 Sep 2018 | PREVYMIS è indicato per la profilassi della riattivazione e della malattia da citomegalovirus (CMV) in pazienti adulti s… | fully innovative, since expired | source |
23 further decisions for letermovir, across 14 agencies, are not shown here. They include the most recent record on file, 17 Dec 2025 from HAS (France); its outcome is in the subscriber dataset. They link to 20 further source documents.
Related molecules
- sofosbuvir — same ATC class J05A — Antivirals
- raltegravir — same ATC class J05A — Antivirals
- cabotegravir — same ATC class J05A — Antivirals
- tenofovir — same ATC class J05A — Antivirals
- darunavir — same ATC class J05A — Antivirals
- dolutegravir — same ATC class J05A — Antivirals
Coverage: 28 decisions for letermovir from 14 agencies, 2017 to 2025. Data to 7 Sep 2026. ATC class J05A — Antivirals. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.